Aging
Navigate
Submit an Article
Research Paper|Volume 12, Issue 5|pp. 4641–4659
Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models
Back to articleFigure 2(2 of 14)
100%
Figure 2
Figure 2.MTS assay of cells treated with different concentration of SLAB51 (left). MTS assay of cells treated with 35 μM 6-OHDA and 35 μM 6-OHDA and SLAB51 0.1mg/ml (right). Data are mean ± SE of three different experiments run in quadruplicate (n=3). *** p< 0.0005 vs Ctr; +++ p< 0.0005 vs 6-OHDA.
Figure 2 — Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson&#x2019;s disease models | Aging